Skip to Content
Watertown Bio
Home
Newsletter
Community Overview
Organization Gallery
Therapeutic Pipeline Overview
Industry Reports
About
Contact
Support Us
(0)
Cart (0)
Support Watertown Bio
Watertown Bio
Home
Newsletter
Community Overview
Organization Gallery
Therapeutic Pipeline Overview
Industry Reports
About
Contact
Support Us
(0)
Cart (0)
Support Watertown Bio
Home
Newsletter
Folder: Life Science Community Info
Back
Community Overview
Organization Gallery
Therapeutic Pipeline Overview
Industry Reports
Folder: About Us
Back
About
Contact
Support Us
Support Watertown Bio
Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market
News Roundup Sam Ghilardi 5/26/26 News Roundup Sam Ghilardi 5/26/26

Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market

Plus the initial dosing of Enanta and Avencell's Clinical Trials

Read More
What we're looking forward to in 2026
News Roundup Sam Ghilardi 1/6/26 News Roundup Sam Ghilardi 1/6/26

What we're looking forward to in 2026

Neumora's positive clinical data , new tenants at the Arsenal, and more

Read More
News Roundup Sam Ghilardi 12/2/25 News Roundup Sam Ghilardi 12/2/25

Cultivarium's Next Steps

Stratus Therapeutics winding down, Consider the ALS TDI for Giving Tuesday, and more

Read More

Watertown Bio

Contact

info@watertown.bio